Navigation Links
Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone

nti-cancer drugs following disease relapse. Pixantrone, a novel anthracenedione analog, was developed to reduce treatment-related cardiotoxicity while retaining efficacy.

These findings suggest that pixantrone may have potential use in patients heavily pre-treated with anthracyclines, in patients with cardiac disorders, and in patients who might benefit from longer-term anthracycline therapy than can be administered with currently approved agents.

Details of the Preclinical Studies

The studies were designed to evaluate the potential cardiotoxicity of pixantrone in mice pre-treated with doxorubicin and to evaluate the potential cardiotoxicity of pixantrone as a single agent compared to doxorubicin and mitoxantrone. Mice pre-treated with a cardiotoxic dose of doxorubicin were then administered a saline placebo control, doxorubicin, pixantrone, or mitoxantrone. Mice that received a second cycle of doxorubicin or mitoxantrone developed marked or severe cardiotoxicity. Mice that received the placebo or pixantrone as the second cycle had slightly increased mean total cardiotoxicity score, indicating that earlier exposure to doxorubicin may continue to damage the heart. While cardiotoxicity observed in the mice treated with pixantrone was not statistically different compared to mice treated with placebo, it was statistically different from that observed in the groups treated with doxorubicin or mitoxantrone. In the mice pre-treated with doxorubicin, a second cycle of mitoxantrone or pixantrone resulted in mortality of 33 percent and 27 percent, respectively.

Mice that received two consecutive cycles of pixantrone as a single agent showed no significant cardiotoxicity and had a mean total toxicity score that was statistically similar to the placebo. The severity and extent of observed damage to heart tissue was minimal and considered reversible. However, mice receiving two cycles of doxorubicin or mitoxantrone experienced marked cardiac damage th
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of ... D 2015 enrollment data shows that 81 percent of ... access and extra discounts at certain pharmacies. The findings ... "Preferred pharmacy plans are now the foundation of Medicare ...
(Date:1/23/2015)... 23, 2015  MedScope ( www.medscope.org ), the leading provider ... 2015 Connected World magazine Connected World Award ... that can be used anywhere, anytime. The nomination was ... In nominating MedScope, Landon Garner , Director ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. ... Biotechnology, Inc. for the compounding, packaging and distributing of its ... the United States . ... of compounding naltrexone tablets in various strengths for individual patients ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... MARY, Fla., Sept. 29, 2011 PediaVision today ... is the first in the State of California ... PediaVision called "Spot."  The University,s Department of Ophthalmology ... Riverside County, thanks to the support of ...
... 29, 2011 Atrium Medical Corporation today announced ... Journal of Vascular Surgery.  COBEST ( Covered Versus ... landmark, prospective, multi center, randomized, controlled clinical trial ... covered stent technology is superior to traditional bare ...
Cached Medicine Technology:Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 2Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 3Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 4Atrium Announces the Publication of the COBEST Trial by the Journal of Vascular Surgery 2Atrium Announces the Publication of the COBEST Trial by the Journal of Vascular Surgery 3
(Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... ... leading providers of accounts receivable management services, has moved its National Account Service Center ... ... 2010 -- TekCollect, one of the nation’s leading providers of accounts receivable management ...
... Calif. , Jan. 15 Nearly 7,500 registered nurses have ... to be the largest outpouring of RN volunteers in U.S. history, reports ... clock to find locations for the nurses to deploy on the ground ... the NNU program as well. , View the attached volunteer ...
... SAN FRANCISCO , Jan. 15 A Good Idea ... in San Francisco , plans to give $100,000 to ... the Chase Community Giving contest sponsored by JPMorgan Chase & Co. , ... within the Bay Area, we feel that it is of the utmost importance ...
... To meet ... as part of the coordinated United Nations Flash Appeal. , ... United Nations, NY (Vocus) January 15, 2010 -- Estimates that ... by Haiti’s earthquake have led to an urgent appeal to meet their emergency maternal health ...
... , Jan. 15 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp. ... distributing to shareholders an additional supplement (the "Supplement") to the ... previously delivered to shareholders in connection with the Special Meeting ... . The special meeting was originally held to consider a ...
... provides data on sources of public and private funds , ... the level of funding for biomedical research in the United ... study shows. , The same review also found that the ... An analysis of data showed that funding of biomedical research ...
Cached Medicine News:Health News:TekCollect Opens New National Account Service Center and Corporate Headquarters 2Health News:Nearly 7,500 RNs Ready to Deploy to Haiti 2Health News:San Francisco Charity A GOOD IDEA to Give $100,000 to Haiti Victims Upon Winning Nationwide Charity Program 2Health News:Appeal Launched for Emergency Assistance to Thousands of Pregnant Women at High Risk in Haiti 2Health News:NUCRYST Announces Distribution of Supplemental Information In Connection with Special Meeting of Shareholders 2Health News:NUCRYST Announces Distribution of Supplemental Information In Connection with Special Meeting of Shareholders 3Health News:NUCRYST Announces Distribution of Supplemental Information In Connection with Special Meeting of Shareholders 4Health News:Money for Biomedical Research Cut in Recent Years 2
... The design of the Hi-Top ... to be held back in ... shoe counter. The front is ... and compression on the toes. ...
... post op shoe is ideal for the ... upper will keep your patient both cool ... provides even tension and compression. The reinforced ... for your patient. The black TPR outsole ...
Comfortably positions the affected foot at 90 to provide continuous and effective stretching of the plantar fascia and Achilles Tendon...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Medicine Products: